CoChat

A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)

Open access
West Japan Oncology Group, Iwata, Takekazu, Yoshino, Ichiro, Yoshida, Shigetoshi, Ikeda, Norihiko, Tsuboi, Masahiro, Asato, Yuji, Katakami, Nobuyuki, Sakamoto, Kazuhiro, Yamashita, Yoshinori, Okami, Jiro, Mitsudomi, Tetsuya, Yamashita, Motohiro, Yokouchi, Hiroshi, Okubo, Kenichi, Okada, Morihito, Takenoyama, Mitsuhiro, Chida, Masayuki, Tomii, Keisuke, Matsuura, Motoki, Azuma, Arata, Iwasawa, Tae, Kuwano, Kazuyoshi, Sakai, Shuji, Hiroshima, Kenzo, Fukuoka, Junya, Yoshimura, Kenichi, Tada, Hirohito, Nakagawa, Kazuhiko, Nakanishi, Yoichi · 2016 · Respiratory Research
Cited by 125

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) often accompanies lung cancer, and life-threatening acute exacerbation (AE) of IPF (AE-IPF) is reported to occur in 20 % of IPF patients who undergo lung cancer surgery. Pirfenidone is an anti-fibrotic agent known to reduce disease progression in IPF patients. A phase II study was conducted to evaluate whether perioperative pirfenidone treatment could reduce the incidence of postoperative AE-IPF patients with lung cancer. METHODS: Pirfenidone was orally administered to IPF patients who were candidates for lung cancer surgery; pirfenidone was dosed at 600 mg/day for the first 2 weeks, followed by 1200 mg/day. Surgery was performed after at least 2 weeks of 1200-mg/day administration. The primary endpoint was non-AE-IPF rate during postoperative days 0-30, compared to the null value of 80 %, and the secondary endpoint was safety. Radiologic and pathologic diagnoses of IPF and AE-IPF were confirmed by an independent review committee. RESULTS: From June 2012 to January 2014, 43 cases were enrolled, and 39 were eligible (full analysis set [FAS]). Both pirfenidone treatment and surgery were performed in 36 patients (per protocol set [PPS]). AE-IPF did not occur in 37/39 patients (94.9 % [95 % confidential interval: 82.7-99.4 %, p = 0.01]) in the FAS, and in 38/39 patients (97.2 % [95 % confidential interval: 85.5-99.9 %, p = 0.004] in the PPS. A grade 5 adverse event (death) occurred in 1 patient, after AE-IPF; no other grade 3-5 adverse events were observed. CONCLUSIONS: Perioperative pirfenidone treatment is safe, and is promising for reducing AE-IPF after lung cancer surgery in IPF patients. TRIAL REGISTRATION: This clinical trial was registered with the University Hospital Medical Information Network (UMIN) on April 16th, 2012 (REGISTRATION NUMBER: UMIN000007774 ).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-016-0398-4

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 125

Metadata

Authors
West Japan Oncology Group, Iwata, T., Yoshino, I., Yoshida, S., Ikeda, N., Tsuboi, M., Asato, Y., Katakami, N., Sakamoto, K., Yamashita, Y., Okami, J., Mitsudomi, T., Yamashita, M., Yokouchi, H., Okubo, K., Okada, M., Takenoyama, M., Chida, M., Tomii, K., Matsuura, M., Azuma, A., Iwasawa, T., Kuwano, K., Sakai, S., Hiroshima, K., Fukuoka, J., Yoshimura, K., Tada, H., Nakagawa, K., & Nakanishi, Y.
Venue
Respiratory Research
Published
2016-07-22
Volume
17
Issue
1
Pages
90-90
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2476684925
Cited by
125
References
4
FWCI
11.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). https://app.cochat.ai/papers/10.1186/s12931-016-0398-4
The paper
West Japan Oncology Group, Iwata, T., Yoshino, I., Yoshida, S., Ikeda, N., Tsuboi, M., Asato, Y., Katakami, N., Sakamoto, K., Yamashita, Y., Okami, J., Mitsudomi, T., Yamashita, M., Yokouchi, H., Okubo, K., Okada, M., Takenoyama, M., Chida, M., Tomii, K., . . . Nakanishi, Y. (2016). A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respiratory Research. https://doi.org/10.1186/s12931-016-0398-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.